The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.675
https://www.valueinhealthjournal.com/article/S1098-3015(13)02580-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
649
First Page :
A440
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02580-1&doi=10.1016/j.jval.2013.08.675